jRCT1030260013RecruitingNot Applicable
An observational study on the safety and therapeutic effects of eye drops containing pilocarpine as an active ingredient in subjects with presbyopia (farsightedness)
Not provided0 sites10 target enrollmentStarted: TBD
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Enrollment
- 10
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 20age old over to No limit (—)
- Sex
- All
Inclusion Criteria
- •A case in which pilocarpine-based eye drops were used in patients who had not responded to standard medications
Exclusion Criteria
- •Patients who were unable to continue treatment due to hypersensitivity or allergic reactions to eye drops containing pilocarpine as an active ingredient.
- •Patients who are taking other medications concomitantly, or who have previously participated in clinical trials and have not yet taken the test drug for more than one month.
- •Patients who are otherwise deemed inappropriate by the principal investigator or co-investigator.
Investigators
Similar Trials
Recruiting
Not Applicable
An observational study on the safety and therapeutic effects of oral administration of Quercefit in subjects with aging symptomsAge-related decline in physical function and aging-associated symptomsjRCT103026001810
Recruiting
Phase 2
A study to investigate the safety and clinical activity of belantamab for the treatment of multiple myeloma when used as monotherapy and in combination treatments.Multiple myeloma2022-501941-63-00Glaxosmithkline Research & Development Limited3
Recruiting
Phase 1
A clinical study to investigate the safety, tolerability and pharmacokinetic profile of single ascending concentrations of OPT101 in peritoneal dialysis patients.Chronic kidney disease2025-522966-61-00OPTERION Health AG12
Recruiting
Not Applicable
A Clinical Study of Islatravir/MK-8507 (MK-8591B) in Healthy Japanese ParticipantsHIV infectionjRCT203125065524
Recruiting
Phase 2
Clinical study to evaluate the safety and tolerability of SPVN06 (novel gene therapy) in a subset of patients with rod cone dystrophy (RCD).Inherited retinal dystrophies2022-501250-12-01Sparingvision17